pharmaceutical Logo
Eleven Biotherapeutics logo

Working At Eleven Biotherapeutics

Zippia Score 4.6

Eleven Biotherapeutics overview

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company s lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck. It is also developing systemically-administered TPTs, including VB6-845d for the treatment of multiple types of epithelial cell adhesion molecule positive solid tumors. Eleven Biotherapeutics, Inc. has a cooperative research and development agreement with the National Cancer Institute on the development of the company s targeted therapeutic, Vicinium in combination with AstraZeneca s immune checkpoint inhibitor, ImfinziTM (durvalumab), for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Eleven Biotherapeutics is a small technology company based in Cambridge, Massachusetts with only 35 employees and an annual revenue of $29.9M.

The Organization’s Mission

Discovering and developing innovative ocular therapeutics, and to advance the development of our lead product candidate, EBI-005 for the treatment of moderate to severe allergic conjunctivitis.

Industry

Pharmaceutical

Revenue

$29.9M

Employees

35

Founded in

2008

Headquarters

Cambridge, MA

Website

sesenbio.com

Website

sesenbio.com

Organization Type

Private

Is This Your Company?

The team at Eleven Biotherapeutics

Key People
  • Stephen Hurly (Executive Officer, Director)
  • Paul Chaney (Director)
  • Abbie Celniker (Director)
  • Wendy Dixon (Director)
  • Richard Fitzgerald (Executive Officer)
  • Leslie Dan (Director)
  • Jay Duker (Director)
  • Barry Gertz (Director)
  • Jane Henderson (Director)
  • Daniel Lynch (Director)

What do people say about Eleven Biotherapeutics

Work at Eleven Biotherapeutics ? Share your experience anonymously.

What do you like about working for Eleven Biotherapeutics?

Eleven Biotherapeutics Rankings

Eleven Biotherapeutics is ranked #38 on the Best Start-up Companies to Work For in America list. Zippia's Best Places to Work lists provide unbiased, data-based evaluations of companies. Rankings are based on government and proprietary data on salaries, company financial health, and employee diversity.

Read more about how we rank companies.

00

Do you Work At Eleven Biotherapeutics?

Help us make this company more transparent.

0

Eleven Biotherapeutics Financial Performance

9.8
Performance Score
We calculated the performance score of companies by measuring multiple factors, including revenue, longevity, and stock market performance.

Revenue

$10M - $100M

Founded in

2008

Organization type

Private

Eleven Biotherapeutics Financing Rounds

DateAmount
Apr 5, 2018Equity
$996,016
Sep 28, 2016Equity
$13,525,262
Dec 5, 2014Equity
$20,000,010
Oct 13, 2010Equity
$35,000,000

How Would You Rate The Company Culture Of Eleven Biotherapeutics?

Have you worked at Eleven Biotherapeutics? Help other job seekers by rating Eleven Biotherapeutics.

Eleven Biotherapeutics Competitors

Company
Analytics 4 LifeBiotechnology

Avg: $79,289

BIND BIOSCIENCESBiotechnology

Avg: $79,034

XtalComputers

Avg: $77,457

BAROFOLDLife Sciences Tools and Services

Avg: $76,420

Audentes TherapeuticsBiotechnology

Avg: $76,046

Frequently Asked Questions about Eleven Biotherapeutics

When was Eleven Biotherapeutics founded?

Eleven Biotherapeutics was founded in 2008.

How many Employees does Eleven Biotherapeutics have?

Eleven Biotherapeutics has 35 employees.

How much money does Eleven Biotherapeutics make?

Eleven Biotherapeutics generates $29.9M in revenue.

What industry is Eleven Biotherapeutics in?

Eleven Biotherapeutics is in the pharmaceutical industry.

What is Eleven Biotherapeutics's mission?

Eleven Biotherapeutics's mission statement is "Discovering and developing innovative ocular therapeutics, and to advance the development of our lead product candidate, EBI-005 for the treatment of moderate to severe allergic conjunctivitis."

What type of company is Eleven Biotherapeutics?

Eleven Biotherapeutics is a private company.

Who are Eleven Biotherapeutics's competitors?

Eleven Biotherapeutics competitors include OTHERA PHARM, Liquidia Technologies, Ra Pharmaceuticals, Lung Therapeutics, Cytonics, Oncobiologics, Avitide, DesignMedix, MiniVax, Elemental Machines, InteloMed, Jounce Therapeutics, eNeura Therapeutics, Cristcot, Sedia Biosciences, CALCIMEDICA, Constellation Pharmaceuticals, MEDIQUEST THERAPEUTICS, Ansun Biopharma, Apic Bio.

Who works at Eleven Biotherapeutics?

Stephen Hurly (Executive Officer, Director)

Paul Chaney (Director)

Abbie Celniker (Director)

Show More

Are you an executive, HR leader, or brand manager at Eleven Biotherapeutics?

Claiming and updating your company profile on Zippia is free and easy.

You can find out what it is like to work at Eleven Biotherapeutics, also known as ELEVEN BIOTHERAPEUTICS, Eleven Biotherapeutics, Eleven Biotherapeutics Inc and Eleven Biotherapeutics, Inc..

Zippia gives an in-depth look into the details of Eleven Biotherapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Eleven Biotherapeutics. The employee data is based on information from people who have self-reported their past or current employments at Eleven Biotherapeutics. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions, or for the results obtained from the use of this information. The data presented on this page does not represent the view of Eleven Biotherapeutics and its employees or that of Zippia.